Cupid Limited H1 FY27 Investor Presentation

H1 FY27 Performance (YoY):

Revenue from operations: ₹342.58 Crores, up 137.5% from H1 FY26 (₹144.25 Crores)
Total Income: ₹365.95 Crores, up 136.1% from H1 FY26 (₹154.98 Crores)
EBITDA: ₹114.83 Crores, up 155.8% from H1 FY26 (₹44.89 Crores); Margin: 33.5%
Profit After Tax (PAT): ₹100.37 Crores, up 156.5% from H1 FY26 (₹39.14 Crores); Margin: 29.3%
EPS (bonus-adjusted): ₹0.75, up 158.6% from H1 FY26 (₹0.29)

Q2 FY27 Performance (YoY):

Business Segment Revenue (H1 FY27):

Total Domestic Revenue: ₹224.64 Crores (66.6% of total)
Total Export Revenue: ₹112.73 Crores (33.4% of total)
Male Condoms: ₹74.39 Crores (65.99% of exports)
Female Condoms: ₹23.99 Crores (21.28% of exports)
Lubricants, IVD Kits & FMCG: ₹14.35 Crores (12.73% of exports)

FY26 Full Year Reference:

FY26 Export Revenue: ₹208.13 Crores (59.3% of total FY26 revenue of ₹357.71 Crores)
FY26 Domestic Consumer Revenue: ₹121.61 Crores (34.6% of total revenue)

Style Baazar Investment: Committed ₹331.53 Crores via 1.01 Crore convertible warrants. 45 Lakh warrants converted in October 2026 (₹193.67 Crores deployed), 56 Lakhs pending. Expected FY27 revenue contribution: ~₹200 Crores.
V2 Retail Partnership: Exclusive long-term retail partnership providing 400 sq. ft. of space in each of V2 Retail's 425+ stores. Full network rollout expected by mid-December 2026. Estimated revenue opportunity: ~₹400 Crores over the next 12 months.
GII Healthcare Investment: Follow-on investment of US$5 Million in July 2026 (first stake acquired in 2025). Platform provides access to GCC healthcare and international markets.

Sinnar Plant Current Capacity (p.a.): 480 Million male condoms, 52 Million female condoms, 210 Million lubricant sachets, ~4 Lakhs IVD kits/day.
Palava Plant: Under implementation with ~170,000 sq. ft. Expected commissioning in Q3 FY27. Will increase capacity to ~1.25 Billion male condoms p.a. and ~125 Million female condoms p.a.
IVD Automation: Automation project at Sinnar targeting increase from ~4 Lakhs kits/day to ~8 Lakhs kits/day by end-2027.
International Ventures: In-principle approval for manufacturing venture in South Africa (Cupid stake up to 49%) and exploratory plans for West Bengal manufacturing facility.

Mr. Aditya Kumar Halwasiya, Chairman & Managing Director:

H1 FY27 reflects strong business momentum with 137% growth in operating income
Domestic Consumer Healthcare & FMCG contributed 49% of H1 revenue
Expects H2 FY27 to be stronger than H1 due to Palava commissioning and partnership scaling
Company plans to become debt-free

Revised Guidance:

First company worldwide with WHO/UNFPA prequalification for both male and female condoms
Supplies to 125+ countries through governments, UN agencies (WHO/UNFPA, PFSCM, Global Fund), NGOs, and OEM customers
Holds 59% of South Africa's female condom allocation for 2025-30 program (23.4 Million units p.a.)
CE (EU IVDR) certification for 4 IVD kits (HIV 1&2, Hepatitis B, Syphilis, Pregnancy)
7 consumer brands in India reaching 2 Lakhs+ retail outlets

As of FY26 (from referenced balance sheet):